

# APPENDIX 12: RESULTS FROM SUBGROUP AND SENSITIVITY ANALYSES

## Subgroups Viral Load

**TABLE 146: VIRAL LOAD ≥ THRESHOLD GENOTYPE 1 TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS —RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.86 (1.33 to 2.30)	31.25 (12.22 to 44.45)
SOF12 + LDV12		2.40 (1.89 to 2.84)	51.42 (33.37 to 60.33)
SOF24 + LDV24		1.96 (0.60 to 2.76)	35.05 (−14.39 to 60.79)
SOF8 + LDV8		2.23 (1.36 to 2.79)	45.33 (13.02 to 59.94)
SOF8 + LDV8 + RBV8		2.18 (1.26 to 2.75)	43.47 (9.55 to 58.75)
SOF12 + LDV12 + RBV12		2.20 (1.11 to 2.79)	44.25 (4.00 to 60.53)
SOF24 + LDV24 + RBV24		2.28 (0.85 to 2.88)	47.00 (−5.37 to 63.41)
SIM12 PR24-48 RGT		2.04 (1.70 to 2.41)	37.94 (26.71 to 46.92)
B44 PR48		2.08 (1.40 to 2.77)	39.43 (15.42 to 57.12)
SOF24 + RBV (low dose) 24		0.61 (0.11 to 1.77)	−14.13 (−33.27 to 27.77)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.38 (1.51 to 2.89)	50.83 (18.60 to 62.50)
DCV24 + ASU24		2.33 (2.01 to 2.71)	48.66 (39.65 to 55.82)
SOF12 + PR12		0.53 (0.04 to 2.16)	−16.91 (−35.76 to 42.17)
SOF12 + LDV12	SOF24 + RBV24	1.29 (1.08 to 1.66)	19.68 (5.85 to 34.25)
SOF24 + LDV24		1.06 (0.33 to 1.60)	3.94 (−45.15 to 34.33)
SOF8 + LDV8		1.20 (0.78 to 1.57)	13.90 (−14.82 to 31.59)
SOF8 + LDV8 + RBV8		1.17 (0.73 to 1.55)	11.92 (−17.87 to 30.50)
SOF12 + LDV12 + RBV12		1.18 (0.63 to 1.62)	12.26 (−24.94 to 34.25)
SOF24 + LDV24 + RBV24		1.22 (0.47 to 1.72)	15.25 (−36.12 to 38.98)
SIM12 PR24-48 RGT		1.10 (0.87 to 1.55)	6.64 (−9.73 to 27.33)
B44 PR48		1.12 (0.76 to 1.64)	8.08 (−17.90 to 33.32)
SOF24 + RBV (low dose) 24		0.34 (0.07 to 0.91)	−43.41 (−66.03 to −6.38)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.27 (0.86 to 1.69)	18.63 (−9.61 to 36.66)
DCV24 + ASU24		1.26 (1.03 to 1.75)	17.32 (2.34 to 37.15)
SOF12 + PR12		0.29 (0.02 to 1.17)	−46.64 (−71.10 to 11.28)
SOF24 + LDV24	SOF12 + LDV12	0.82 (0.26 to 1.15)	−15.46 (−62.99 to 12.15)
SOF8 + LDV8		0.94 (0.64 to 1.06)	−5.54 (−29.10 to 5.21)
SOF8 + LDV8 + RBV8		0.92 (0.60 to 1.05)	−7.36 (−32.06 to 3.82)
SOF12 + LDV12 + RBV12		0.92 (0.50 to 1.11)	−6.65 (−42.23 to 9.11)
SOF24 + LDV24 + RBV24		0.96 (0.37 to 1.21)	−3.84 (−53.37 to 15.78)
SIM12 PR24-48 RGT		0.85 (0.72 to 1.08)	−13.53 (−26.24 to 5.94)
B44 PR48		0.86 (0.61 to 1.17)	−11.97 (−34.87 to 12.07)
SOF24 + RBV (low dose) 24		0.26 (0.05 to 0.72)	−63.76 (−84.97 to −23.69)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.70 to 1.15)	-0.55 (-24.52 to 12.01)
DCV24 + ASU24		0.97 (0.85 to 1.23)	-3.01 (-14.01 to 16.16)
SOF12 + PR12		0.22 (0.02 to 0.89)	-66.58 (-87.41 to -9.61)
SOF8 + LDV8	SOF24 + LDV24	1.13 (0.70 to 3.47)	9.46 (-25.18 to 58.65)
SOF8 + LDV8 + RBV8		1.11 (0.65 to 3.44)	7.63 (-29.64 to 57.19)
SOF12 + LDV12 + RBV12		1.11 (0.66 to 2.99)	7.61 (-27.29 to 49.16)
SOF24 + LDV24 + RBV24		1.12 (0.62 to 2.93)	8.77 (-26.46 to 53.79)
SIM12 PR24-48 RGT		1.04 (0.73 to 3.46)	2.87 (-25.35 to 52.61)
B44 PR48		1.06 (0.66 to 3.63)	4.37 (-31.14 to 58.04)
SOF24 + RBV (low dose) 24		0.34 (0.06 to 1.48)	-43.62 (-85.61 to 13.26)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.19 (0.77 to 3.77)	13.99 (-19.76 to 64.20)
DCV24 + ASU24		1.19 (0.86 to 4.03)	13.47 (-13.60 to 64.57)
SOF12 + PR12		0.29 (0.05 to 0.83)	-43.09 (-70.34 to -11.97)
SOF8 + LDV8 + RBV8	SOF8 + LDV8	0.98 (0.74 to 1.23)	-1.79 (-19.37 to 13.78)
SOF12 + LDV12 + RBV12		0.99 (0.53 to 1.51)	-1.02 (-38.51 to 28.28)
SOF24 + LDV24 + RBV24		1.02 (0.40 to 1.65)	1.80 (-48.98 to 34.74)
SIM12 PR24-48 RGT		0.91 (0.73 to 1.51)	-7.36 (-24.56 to 25.56)
B44 PR48		0.93 (0.65 to 1.60)	-5.80 (-31.49 to 30.56)
SOF24 + RBV (low dose) 24		0.28 (0.05 to 0.82)	-56.32 (-82.34 to -12.64)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.05 (0.89 to 1.35)	4.44 (-8.14 to 20.52)
DCV24 + ASU24		1.04 (0.86 to 1.71)	3.03 (-12.66 to 35.47)
SOF12 + PR12		0.24 (0.02 to 0.98)	-58.43 (-86.13 to -1.58)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	1.01 (0.55 to 1.58)	0.70 (-36.45 to 30.25)
SOF24 + LDV24 + RBV24		1.04 (0.42 to 1.75)	3.24 (-45.72 to 37.53)
SIM12 PR24-48 RGT		0.93 (0.74 to 1.62)	-5.65 (-23.62 to 29.01)
B44 PR48		0.95 (0.65 to 1.72)	-4.00 (-30.24 to 34.35)
SOF24 + RBV (low dose) 24		0.29 (0.05 to 0.85)	-54.05 (-81.93 to -9.73)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.08 (0.83 to 1.55)	6.43 (-12.87 to 28.89)
DCV24 + ASU24		1.06 (0.87 to 1.84)	4.84 (-11.70 to 39.22)
SOF12 + PR12		0.25 (0.02 to 1.02)	-56.23 (-85.09 to 1.14)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.02 (0.47 to 1.90)	1.81 (-39.78 to 40.89)
SIM12 PR24-48 RGT		0.92 (0.73 to 1.84)	-6.19 (-25.46 to 34.32)
B44 PR48		0.95 (0.64 to 1.95)	-4.02 (-32.36 to 40.04)
SOF24 + RBV (low dose) 24		0.30 (0.05 to 0.89)	-54.09 (-84.13 to -6.18)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.07 (0.72 to 2.03)	5.44 (-22.89 to 44.69)
DCV24 + ASU24		1.05 (0.86 to 2.10)	4.20 (-13.34 to 44.76)
SOF12 + PR12		0.25 (0.02 to 0.94)	-55.15 (-83.64 to -4.48)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 PR24-48 RGT	SOF24 + LDV24 + RBV24	0.89 (0.70 to 2.42)	-9.23 (-28.62 to 44.09)
B44 PR48		0.92 (0.61 to 2.47)	-6.90 (-36.43 to 47.26)
SOF24 + RBV (low dose) 24		0.29 (0.05 to 1.08)	-56.75 (-87.83 to 3.07)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.03 (0.68 to 2.68)	2.62 (-28.67 to 54.56)
DCV24 + ASU24		1.02 (0.83 to 2.78)	1.57 (-16.85 to 54.72)
SOF12 + PR12		0.25 (0.03 to 0.93)	-55.86 (-88.32 to -4.52)
B44 PR48	SIM12 PR24-48 RGT	1.02 (0.70 to 1.32)	1.65 (-23.42 to 21.46)
SOF24 + RBV (low dose) 24		0.30 (0.05 to 0.87)	-51.53 (-73.02 to -9.16)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.17 (0.73 to 1.42)	12.62 (-20.19 to 27.69)
DCV24 + ASU24		1.14 (0.98 to 1.36)	10.69 (-1.27 to 22.95)
SOF12 + PR12		0.26 (0.02 to 1.08)	-54.47 (-75.45 to 5.73)
SOF24 + RBV (low dose) 24	B44 PR48	0.30 (0.05 to 0.91)	-52.26 (-79.67 to -5.93)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.14 (0.70 to 1.63)	10.76 (-24.69 to 35.45)
DCV24 + ASU24		1.12 (0.89 to 1.60)	9.20 (-9.64 to 32.69)
SOF12 + PR12		0.25 (0.02 to 1.10)	-54.88 (-83.32 to 7.00)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SOF24 + RBV (low dose) 24	3.77 (1.31 to 20.36)	61.58 (17.65 to 86.32)
DCV24 + ASU24		3.79 (1.32 to 21.36)	62.39 (20.16 to 82.68)
SOF12 + PR12		0.87 (0.06 to 8.59)	-2.32 (-47.95 to 59.57)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.97 (0.83 to 1.55)	-2.30 (-15.77 to 30.24)
SOF12 + PR12		0.23 (0.02 to 0.91)	-63.74 (-90.20 to -6.39)
SOF12 + PR12	DCV24 + ASU24	0.23 (0.02 to 0.93)	-65.40 (-85.63 to -5.60)
Random effect model	Residual deviance	27.1 vs. 29 data points	
	Deviance information criteria	167.03	
Fixed effect model	Residual deviance	26.28 vs. 29 data points	
	Deviance information criteria	165.097	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.